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Results: Based on planar dose measurements we found that 
shielding plate attenuates the beam homogenously over its 
surface. Transmission coefficients for 0.5 cm thick disk were 
0.857, 0.875, 0.872 and 0,855 for 4 MeV, 6 MeV, 9 MeV 
respectively. For 1.0 cm thick plate measured transmission 
coefficients equaled 0.667, 0.714, 0.737 and 0.739 for 4 MeV, 
6 MeV, 9 MeV respectively. 
Table 1 presents surface dose values for different electron 
energies with and without bolus cap. The shifts between 
PDDs with and without bolus cap were estimated as 0.75 cm, 
0.40 cm, 0.30 cm and 0.45 cm for 4 MeV, 6 MeV, 9 MeV 
respectively (Figure 1). 
The dose increase resulting from backscatter radiation (up to 
13.21%, 10.99% and 10.25% for 6 MeV, 9 MeV and 12 MeV 
respectively) in front of the shielding plate was observed. 
The dose increase for 4 MeV electron beam energy was 
negligible. 
 4 MeV 6 MeV 9 MeV 12 MeV 
no bolus 84,67% 89,29% 91,35% 92,36% 




Conclusions: Attenuation of shielding plates was verified and 
transmission coefficients were calculated. Considerable dose 
increase in front of the shielding plate was observed for 
electron beam energies higher than 4 MeV. We observed a 
significant increase in surface dose, especially for lower 
electron beam energies. 
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Purpose/Objective: The aim of this work is to evaluate the 
feasibility of ArcCHECK (AC) and 3DVH v3.1.0 software 
(SunNuclear Corporation) for QA verification of VMAT patient 
plans with very small fields, FFF beams, high dose rates and 
high absorbed doses. We use other traditional QA systems 
such as Gafchromic EBT3 film, and dose point with a PinPoint 
(PTW) ionization chamber for comparison as well. 
Materials and Methods: Four RapidArc plans with very small 
targets in different body locations and different beam 
energies were selected: usual head SRS (4.9 cm3) with X6FF 
beam energy and dose rate up to 600 MU/min, a head SRS 
(4.9 cm3) with X6FFF and up to 1400 MU/min, a lung SBRT 
(18.1 cm3) with X6FFF and up to 1400 MU/min in order to 
deal with heterogeneities and an abdominal SBRT (53.4 cm3) 
with X10FFF beam energy and dose rate up to 2400 MU/min 
(maximum dose rate). The 3D dose distributions were 
calculated by Eclipse with AAA v10.28 algorithm. 
Measurements were performed in a Varian TrueBeam Linac 
2.0. All treatment plans were verified by AC system. 
Measurements with the diode array were compared with TPS 
calculations assessed in AC phantom virtual image set with an 
homogeneous mass density of 1.19 g/cm3. 3D gamma analysis 
was used for the comparison. 
For EBT3 film and PinPoint measurements, a cylindrical solid 
water phantom was used. 2D gamma analysis was used to 
compare film's planar dose distribution with the TPS in the 
convenient plane of the cylindrical phantom. Seven points 
were taken into account for chamber measurements in order 
to assess setup uncertainties, considering a potential setup 
error of 1 mm in any direction. 
In the three different systems, measurement to calculation 
comparisons were evaluated under usual passing rate gamma 
analysis global and local criteria: 3%/3 mm, 2%/2 mm and 
1%/1 mm, dose difference and DTA, with a threshold pf a 10% 
maximum dose. 
3DVH software was also evaluated assessing AC dose 
measurements inside the patient CT image set and comparing 
with the TPS calculations. 




Comparing 3DVH results with histograms calculated by TPS, 
differences around 4-8% on average were found in ICRU 83 
parameters for PTV, GTV, ITV and OARs. 
Conclusions: Global and local gamma passing rate analysis 
were done for AC and EBT3 film under γ(3%/3 mm), γ(2%/2 
mm) and γ(1%/1 mm) criteria. Point dose measurements with 
PinPoint chamber were also done. Results with film and 
chamber, used as a gold standard, warrant that AC 
measurements were in good agreement with TPS 
calculations. 3DVH has proven to be a good tool to assess 
dose distribution inside the patient. Thus AC with 3DVH is 
suitable for clinical use under FFF beams, very small fields, 
high dose rates and high absorbed doses conditions as long as 
4% to 8% differences are considered to be acceptable.  
 
 
 
 
 
 
 
